{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T07:38:54Z","timestamp":1780817934500,"version":"3.54.1"},"reference-count":115,"publisher":"Elsevier BV","issue":"28","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.vaccine.2021.05.016","type":"journal-article","created":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T20:21:18Z","timestamp":1620937278000},"page":"3666-3677","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":72,"title":["U.S. Population-Based background incidence rates of medical conditions for use in safety assessment of COVID-19 vaccines"],"prefix":"10.1016","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1877-7419","authenticated-orcid":false,"given":"Diane","family":"Gubernot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelia","family":"Jazwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manette","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Baumblatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julianne","family":"Gee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Moro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Duffy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"Harrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael M.","family":"McNeil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Broder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Kamidani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine K.","family":"Olson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakshmi","family":"Panagiotakopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Shimabukuro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Forshee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2021.05.016_b0005","unstructured":"World Health Organization. WHO Director-General's statement on IHR Emergency Committee on Novel Coronavirus (2019-nCoV). https:\/\/www.who.int\/dg\/speeches\/detail\/who-director-general-s-statement-on-ihr-emergency-committee-on-novel-coronavirus-(2019-ncov), 2020 [Accessed 6 November 2020]."},{"key":"10.1016\/j.vaccine.2021.05.016_b0010","unstructured":"World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard. https:\/\/covid19.who.int; 2020 [Accessed 28 February 2021]."},{"key":"10.1016\/j.vaccine.2021.05.016_b0015","first-page":"1","article-title":"Safety of Vaccines Used for Routine Immunization in the United States","volume":"215","author":"Maglione","year":"2014","journal-title":"Evid Rep Technol Assess (Full Rep)."},{"key":"10.1016\/j.vaccine.2021.05.016_b0020","unstructured":"U.S. Food and Drug Administration. COVID-19 Vaccines. https:\/\/www.fda.gov\/emergency-preparedness-and-response\/coronavirus-disease-2019-covid-19\/covid-19-vaccines; 2021 [Accessed 29 January 2021]."},{"key":"10.1016\/j.vaccine.2021.05.016_b0025","doi-asserted-by":"crossref","unstructured":"Gee J, Marquez M, Su J, et al. et al. First month of COVID-19 vaccine safety monitoring in the United States. MMWR Morb Mortal Wkly Rep 2021; in progress.","DOI":"10.15585\/mmwr.mm7008e3"},{"key":"10.1016\/j.vaccine.2021.05.016_b0030","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.25594","article-title":"Factors Associated With US Adults' Likelihood of Accepting COVID-19 Vaccination","volume":"3","author":"Kreps","year":"2020","journal-title":"JAMA Netw Open."},{"key":"10.1016\/j.vaccine.2021.05.016_b0035","unstructured":"VAERS. Vaccine Adverse Event Reporting System. www.VAERS.HHS.GOV; 2020 [Accessed 6 November 2020]."},{"issue":"19","key":"10.1016\/j.vaccine.2021.05.016_b0040","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1001\/jama.2020.19692","article-title":"Postapproval Vaccine Safety Surveillance for COVID-19 Vaccines in the US","volume":"324","author":"Lee","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2021.05.016_b0045","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(09)61877-8","article-title":"Importance of background rates of disease in assessment of vaccine safety during mass immunisation with pandemic H1N1 influenza vaccines","volume":"374","author":"Black","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2021.05.016_b0050","unstructured":"Centers for Disease Control and Prevention. General questions and answers on Guillain-Barre syndrome (GBS). Atlanta, GA: Centers for Disease Control and Prevention. https:\/\/www.cdc.gov\/h1n1flu\/vaccination\/gbs_qa.htm; 2009 [Accessed 23 November 2020]."},{"key":"10.1016\/j.vaccine.2021.05.016_b0055","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1159\/000324710","article-title":"Population incidence of Guillain-Barr\u00e9 syndrome: a systematic review and meta-analysis","volume":"36","author":"Sejvar","year":"2011","journal-title":"Neuroepidemiology."},{"key":"10.1016\/j.vaccine.2021.05.016_b0060","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1159\/000339248","article-title":"Guillain-Barr\u00e9 syndrome incidence in a large United States cohort (2000\u20132009)","volume":"39","author":"Shui","year":"2012","journal-title":"Neuroepidemiology."},{"key":"10.1016\/j.vaccine.2021.05.016_b0065","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.vaccine.2009.10.115","article-title":"Rates of autoimmune diseases in Kaiser Permanente for use in vaccine adverse event safety studies","volume":"28","author":"Klein","year":"2010","journal-title":"Vaccine."},{"key":"10.1016\/j.vaccine.2021.05.016_b0070","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1212\/01.wnl.0000310983.38724.d4","article-title":"Guillain-Barr\u00e9 syndrome: incidence and mortality rates in US hospitals","volume":"70","author":"Alshekhlee","year":"2008","journal-title":"Neurology."},{"key":"10.1016\/j.vaccine.2021.05.016_b0075","article-title":"Estimation of the Incidence of Guillain-Barr\u00e9 Syndrome During Pregnancy in the United States. Open Forum","author":"Myers","year":"20196071","journal-title":"Infect Dis."},{"key":"10.1016\/j.vaccine.2021.05.016_b0080","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jns.2017.04.006","article-title":"Incidence and clinical characteristics of Guillain-Barr\u00e9 syndrome before the introduction of Zika virus in Puerto Rico","volume":"377","author":"Salinas","year":"2017","journal-title":"J Neurol Sci."},{"key":"10.1016\/j.vaccine.2021.05.016_b0085","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1093\/aje\/kws196","article-title":"Guillain-Barre syndrome during the 2009\u20132010 H1N1 influenza vaccination campaign: population-based surveillance among 45 million Americans","volume":"175","author":"Wise","year":"2012","journal-title":"Am J Epidemiol."},{"key":"10.1016\/j.vaccine.2021.05.016_b0090","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1093\/aje\/kws195","article-title":"Risk of confirmed Guillain-Barre syndrome following receipt of monovalent inactivated influenza A (H1N1) and seasonal influenza vaccines in the Vaccine Safety Datalink Project, 2009\u20132010","volume":"175","author":"Greene","year":"2012","journal-title":"Am J Epidemiol."},{"key":"10.1016\/j.vaccine.2021.05.016_b0095","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1093\/aje\/kwt051","article-title":"Chart-confirmed guillain-barre syndrome after 2009 H1N1 influenza vaccination among the Medicare population, 2009\u20132010","volume":"178","author":"Polakowski","year":"2013","journal-title":"Am J Epidemiol."},{"key":"10.1016\/j.vaccine.2021.05.016_b0100","first-page":"657","article-title":"Preliminary results: surveillance for Guillain-Barr\u00e9 syndrome after receipt of influenza A (H1N1) 2009 monovalent vaccine \u2014 United States, 2009\u20132010","volume":"59","author":"Centers for Disease Control and Prevention","year":"2010","journal-title":"MMWR Morb Mortal Wkly Rep."},{"key":"10.1016\/j.vaccine.2021.05.016_b0105","doi-asserted-by":"crossref","first-page":"696","DOI":"10.2105\/AJPH.2013.301651","article-title":"Cumulative risk of Guillain-Barr\u00e9 syndrome among vaccinated and unvaccinated populations during the 2009 H1N1 influenza pandemic","volume":"104","author":"Vellozzi","year":"2014","journal-title":"Am J Public Health."},{"key":"10.1016\/j.vaccine.2021.05.016_b0110","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1093\/cid\/cit222","article-title":"Lack of association of Guillain-Barr\u00e9 syndrome with vaccinations","volume":"57","author":"Baxter","year":"2013","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.vaccine.2021.05.016_b0115","article-title":"Guillain-Barre syndrome and COVID-19: an observational multicentre study from two Italian hotspot regions","author":"Filosto","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"10.1016\/j.vaccine.2021.05.016_b0120","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1212\/WNL.0b013e3182918cc2","article-title":"Incidence of multiple sclerosis in multiple racial and ethnic groups","volume":"80","author":"Langer-Gould","year":"2013","journal-title":"Neurology."},{"key":"10.1016\/j.vaccine.2021.05.016_b0125","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1212\/WNL.0b013e31822facdd","article-title":"Incidence of acquired CNS demyelinating syndromes in a multiethnic cohort of children","volume":"77","author":"LangerGould","year":"2011","journal-title":"Neurology."},{"key":"10.1016\/j.vaccine.2021.05.016_b0130","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1212\/01.WNL.0000094316.90240.EB","article-title":"Incidence and prevalence of multiple sclerosis in Olmsted County, Minnesota, 1985\u20132000","volume":"61","author":"Mayr","year":"2003","journal-title":"Neurology."},{"key":"10.1016\/j.vaccine.2021.05.016_b0135","unstructured":"Williams VF, Stahlman S, Ying S. Multiple sclerosis among service members of the active and reserve components of the U.S. Armed Forces and among other beneficiaries of the Military Health System, 2007\u20132016. Msmr. 2017;24:2\u201311."},{"key":"10.1016\/j.vaccine.2021.05.016_b0140","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1001\/archneur.1993.00540050074019","article-title":"Transverse myelitis. Retrospective analysis of 33 cases, with differentiation of cases associated with multiple sclerosis and parainfectious events","volume":"50","author":"Jeffery","year":"1993","journal-title":"Arch Neurol."},{"key":"10.1016\/j.vaccine.2021.05.016_b0145","doi-asserted-by":"crossref","first-page":"e414","DOI":"10.1212\/WNL.0000000000007828","article-title":"Aquaporin-4 and MOG autoantibody discovery in idiopathic transverse myelitis epidemiology","volume":"93","author":"Sechi","year":"2019","journal-title":"Neurology."},{"key":"10.1016\/j.vaccine.2021.05.016_b0150","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ajo.2020.07.014","article-title":"Population-Based Incidence of Optic Neuritis in the Era of Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Antibodies","volume":"220","author":"Hassan","year":"2020","journal-title":"Am J Ophthalmol."},{"key":"10.1016\/j.vaccine.2021.05.016_b0155","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1212\/WNL.45.2.244","article-title":"Optic neuritis: a population-based study in Olmsted County","volume":"45","author":"Rodriguez","year":"1995","journal-title":"Minnesota. Neurology."},{"key":"10.1016\/j.vaccine.2021.05.016_b0160","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1212\/WNL.0b013e3181aaea47","article-title":"Incidence and prevalence of CIDP and the association of diabetes mellitus","volume":"73","author":"Laughlin","year":"2009","journal-title":"Neurology."},{"key":"10.1016\/j.vaccine.2021.05.016_b0165","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1159\/000494291","article-title":"Incidence and Prevalence of Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A Systematic Review and Meta-Analysis","volume":"52","author":"Broers","year":"2019","journal-title":"Neuroepidemiology."},{"key":"10.1016\/j.vaccine.2021.05.016_b0170","doi-asserted-by":"crossref","DOI":"10.1007\/s00415-020-10115-y","article-title":"Systematic literature review of burden of illness in chronic inflammatory demyelinating polyneuropathy (CIDP)","author":"Querol","year":"2020","journal-title":"J Neurol."},{"key":"10.1016\/j.vaccine.2021.05.016_b0175","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jpeds.2018.10.044","article-title":"Temporal Trends of Pediatric Hospitalizations with Acute Disseminated Encephalomyelitis in the United States: An Analysis from 2006 to 2014 using National Inpatient Sample","volume":"206","author":"Bhatt","year":"2019","journal-title":"J Pediatr."},{"key":"10.1016\/j.vaccine.2021.05.016_b0180","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1097\/01.inf.0000133048.75452.dd","article-title":"Acute disseminated encephalomyelitis in childhood: epidemiologic, clinical and laboratory features","volume":"23","author":"Leake","year":"2004","journal-title":"Pediatr Infect Dis J."},{"key":"10.1016\/j.vaccine.2021.05.016_b0185","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1097\/EDE.0000000000000210","article-title":"Acute disseminated encephalomyelitis following influenza vaccine","volume":"26","author":"Pellegrino","year":"2015","journal-title":"Epidemiology."},{"key":"10.1016\/j.vaccine.2021.05.016_b0190","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1093\/infdis\/154.3.399","article-title":"Epidemiology of central nervous system infections in Olmsted County, Minnesota, 1950\u20131981","volume":"154","author":"Nicolosi","year":"1986","journal-title":"J Infect Dis."},{"key":"10.1016\/j.vaccine.2021.05.016_b0195","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1097\/00006454-199705000-00009","article-title":"Risk of hospitalization because of aseptic meningitis after measles-mumps-rubella vaccination in one- to two-year-old children: an analysis of the Vaccine Safety Datalink (VSD) Project","volume":"16","author":"Black","year":"1997","journal-title":"Pediatr Infect Dis J."},{"key":"10.1016\/j.vaccine.2021.05.016_b0200","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1212\/WNL.0000000000000086","article-title":"Burden of encephalitis-associated hospitalizations in the United States, 1998\u20132010","volume":"82","author":"Vora","year":"2014","journal-title":"Neurology."},{"key":"10.1016\/j.vaccine.2021.05.016_b0205","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0104169","article-title":"Encephalitis hospitalization rates and inpatient mortality in the United States, 2000\u20132010","volume":"9","author":"George","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2021.05.016_b0210","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/ana.25131","article-title":"Autoimmune encephalitis epidemiology and a comparison to infectious encephalitis","volume":"83","author":"Dubey","year":"2018","journal-title":"Ann Neurol."},{"key":"10.1016\/j.vaccine.2021.05.016_b0215","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.vaccine.2011.10.104","article-title":"Lack of association between childhood immunizations and encephalitis in California, 1998\u20132008","volume":"30","author":"Pahud","year":"2012","journal-title":"Vaccine."},{"key":"10.1016\/j.vaccine.2021.05.016_b0220","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1528-1157.1993.tb02586.x","article-title":"Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935\u20131984","volume":"34","author":"Hauser","year":"1993","journal-title":"Epilepsia."},{"key":"10.1016\/j.vaccine.2021.05.016_b0225","first-page":"1431","article-title":"Estimating the incidence of first unprovoked seizure and newly diagnosed epilepsy in the low-income urban community of Northern Manhattan","volume":"49","author":"Benn","year":"2008","journal-title":"New York City. Epilepsia."},{"key":"10.1016\/j.vaccine.2021.05.016_b0230","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/j.1528-1157.1999.tb00748.x","article-title":"The incidence of epilepsy and unprovoked seizures in multiethnic, urban health maintenance organizations","volume":"40","author":"Annegers","year":"1999","journal-title":"Epilepsia."},{"key":"10.1016\/j.vaccine.2021.05.016_b0235","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1001\/jamaneurol.2019.3258","article-title":"Trends in Stroke Incidence Rates in Older US Adults: An Update From the Atherosclerosis Risk in Communities (ARIC) Cohort Study","volume":"77","author":"Koton","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.vaccine.2021.05.016_b0240","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1001\/jama.2014.7692","article-title":"Stroke incidence and mortality trends in US communities, 1987 to 2011","volume":"312","author":"Koton","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2021.05.016_b0245","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1177\/1747493016654490","article-title":"Trends in hospitalizations and cost associated with stroke by age, United States 2003\u20132012","volume":"11","author":"Tong","year":"2016","journal-title":"Int J Stroke."},{"key":"10.1016\/j.vaccine.2021.05.016_b0250","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1212\/WNL.0000000000004325","article-title":"Sex-specific stroke incidence over time in the Greater Cincinnati\/Northern Kentucky Stroke Study","volume":"89","author":"Madsen","year":"2017","journal-title":"Neurology."},{"key":"10.1016\/j.vaccine.2021.05.016_b0255","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1161\/01.CIR.0000157736.19739.D0","article-title":"Ischemic stroke subtype incidence among whites, blacks, and Hispanics: the Northern Manhattan Study","volume":"111","author":"White","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.vaccine.2021.05.016_b0260","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1212\/WNL.0000000000000519","article-title":"Intracerebral hemorrhage mortality is not changing despite declining incidence","volume":"82","author":"Zahuranec","year":"2014","journal-title":"Neurology."},{"key":"10.1016\/j.vaccine.2021.05.016_b0265","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1002\/ana.23972","article-title":"Persistent ischemic stroke disparities despite declining incidence in Mexican Americans","volume":"74","author":"Morgenstern","year":"2013","journal-title":"Ann Neurol."},{"key":"10.1016\/j.vaccine.2021.05.016_b0270","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1161\/CIRCULATIONAHA.108.772285","article-title":"Incidence and risk factors for stroke in American Indians: the Strong Heart Study","volume":"118","author":"Zhang","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.vaccine.2021.05.016_b0275","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1161\/STROKEAHA.109.564633","article-title":"Imaging data reveal a higher pediatric stroke incidence than prior US estimates","volume":"40","author":"Agrawal","year":"2009","journal-title":"Stroke"},{"key":"10.1016\/j.vaccine.2021.05.016_b0280","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1212\/01.WNL.0000078894.79866.95","article-title":"Risk of stroke in children: ethnic and gender disparities","volume":"61","author":"Fullerton","year":"2003","journal-title":"Neurology."},{"key":"10.1016\/j.vaccine.2021.05.016_b0285","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1093\/milmed\/usy343","article-title":"An Association Between Herpes Zoster Vaccination and Stroke Reduction Among Elderly Individuals","volume":"184","author":"Klaric","year":"2019","journal-title":"Mil Med."},{"key":"10.1016\/j.vaccine.2021.05.016_b0290","doi-asserted-by":"crossref","first-page":"e228","DOI":"10.1542\/peds.2008-2384","article-title":"Varicella vaccination and ischemic stroke in children: is there an association?","volume":"123","author":"Donahue","year":"2009","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2021.05.016_b0295","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1212\/WNL.0000000000000987","article-title":"Narcolepsy and influenza A(H1N1) pandemic 2009 vaccination in the United States","volume":"83","author":"Duffy","year":"2014","journal-title":"Neurology."},{"key":"10.1016\/j.vaccine.2021.05.016_b0300","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1093\/sleep\/25.2.197","article-title":"The epidemiology of narcolepsy in Olmsted County, Minnesota: a population-based study","volume":"25","author":"Silber","year":"2002","journal-title":"Sleep"},{"key":"10.1016\/j.vaccine.2021.05.016_b0305","unstructured":"Manda YR, Baradhi KM. Myopericarditis. Treasure Island, FL: StatPearls Publishing. https:\/\/www.statpearls.com\/articlelibrary\/viewarticle\/25485\/; 2020 [accessed 3 December 2020]."},{"key":"10.1016\/j.vaccine.2021.05.016_b0310","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1159\/000445206","article-title":"Acute Pericarditis-Associated Hospitalization in the USA: A Nationwide Analysis, 2003\u20132012","volume":"135","author":"Kumar","year":"2016","journal-title":"Cardiology."},{"key":"10.1016\/j.vaccine.2021.05.016_b0315","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1093\/ehjqcco\/qcx040","article-title":"Trends in acute pericarditis hospitalizations and outcomes among the elderly in the USA, 1999\u20132012","volume":"4","author":"Mody","year":"2018","journal-title":"Eur Heart J Qual Care Clin Outcomes."},{"key":"10.1016\/j.vaccine.2021.05.016_b0320","doi-asserted-by":"crossref","first-page":"18","DOI":"10.7205\/MILMED-D-12-00226","article-title":"Myopericarditis and pericarditis in the deployed military member: a retrospective series","volume":"178","author":"Lin","year":"2013","journal-title":"Mil Med."},{"key":"10.1016\/j.vaccine.2021.05.016_b0325","doi-asserted-by":"crossref","first-page":"3283","DOI":"10.1001\/jama.289.24.3283","article-title":"Myopericarditis following smallpox vaccination among vaccinia-naive US military personnel","volume":"289","author":"Halsell","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2021.05.016_b0330","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1093\/aje\/kwh269","article-title":"Myopericarditis following smallpox vaccination","volume":"160","author":"Arness","year":"2004","journal-title":"Am J Epidemiol."},{"issue":"Suppl 3","key":"10.1016\/j.vaccine.2021.05.016_b0335","doi-asserted-by":"crossref","first-page":"S242","DOI":"10.1086\/524747","article-title":"Myocarditis, pericarditis, and dilated cardiomyopathy after smallpox vaccination among civilians in the United States, January-October 2003","volume":"46","author":"Morgan","year":"2008","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.vaccine.2021.05.016_b0340","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1016\/j.vaccine.2018.02.030","article-title":"Myocarditis and pericarditis are rare following live viral vaccinations in adults","volume":"36","author":"Kuntz","year":"2018","journal-title":"Vaccine."},{"key":"10.1016\/j.vaccine.2021.05.016_b0345","doi-asserted-by":"crossref","unstructured":"Huang W, Goldberg RJ, Anderson FA, Kiefe CI, Spencer FA. Secular trends in occurrence of acute venous thromboembolism: the Worcester VTE study (1985\u20132009). Am J Med. 2014;127:829\u201339.e5.","DOI":"10.1016\/j.amjmed.2014.03.041"},{"key":"10.1016\/j.vaccine.2021.05.016_b0350","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1001\/archinte.158.6.585","article-title":"Trends in the Incidence of Deep Vein Thrombosis and Pulmonary Embolism: A 25-Year Population-Based Study","volume":"158","author":"Silverstein","year":"1998","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.vaccine.2021.05.016_b0355","doi-asserted-by":"crossref","first-page":"S495","DOI":"10.1016\/j.amepre.2009.12.017","article-title":"Venous thromboembolism: a public health concern","volume":"38","author":"Beckman","year":"2010","journal-title":"Am J Prev Med."},{"key":"10.1016\/j.vaccine.2021.05.016_b0360","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/j.amjcard.2004.01.061","article-title":"Regional differences in rates of diagnosis and mortality of pulmonary thromboembolism","volume":"93","author":"Stein","year":"2004","journal-title":"Am J Cardiol."},{"key":"10.1016\/j.vaccine.2021.05.016_b0365","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1161\/CIR.0000000000000757","article-title":"Heart Disease and Stroke Statistics-2020 Update: A Report From the American Heart Association","volume":"141","author":"Virani","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.vaccine.2021.05.016_b0370","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1001\/jama.2010.529","article-title":"Pneumococcal vaccination and risk of acute myocardial infarction and stroke in men","volume":"303","author":"Tseng","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2021.05.016_b0375","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1093\/aje\/kwf073","article-title":"Influenza vaccination is not associated with a reduction in the risk of recurrent coronary events","volume":"156","author":"Jackson","year":"2002","journal-title":"Am J Epidemiol."},{"key":"10.1016\/j.vaccine.2021.05.016_b0380","unstructured":"Centers for Disease Control and Prevention. LCWK2. Deaths, percent of total deaths, and death rates for the 15 leading causes of death in 10-year age groups, by race and Hispanic origin, and sex: United States, 2017. Hyattsville, MD: National Center for Health Statistics; 2018a."},{"key":"10.1016\/j.vaccine.2021.05.016_b0385","unstructured":"Centers for Disease Control and Prevention. National Vital Statistics System, Mortality 2017: LCWK4. Infant, neonatal, and postnatal deaths, percent of total deaths, and mortality rates for the 15 leading causes of infant death, by race and Hispanic origin, and sex: United States, 2017. Hyattsville, MD: National Center for Health Statistics; 2018b."},{"key":"10.1016\/j.vaccine.2021.05.016_b0390","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1093\/cid\/civ423","article-title":"Deaths Reported to the Vaccine Adverse Event Reporting System, United States, 1997\u20132013","volume":"61","author":"Moro","year":"2015","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.vaccine.2021.05.016_b0395","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.amepre.2013.02.020","article-title":"Mortality rates and cause-of-death patterns in a vaccinated population","volume":"45","author":"McCarthy","year":"2013","journal-title":"Am J Prev Med."},{"key":"10.1016\/j.vaccine.2021.05.016_b0400","doi-asserted-by":"crossref","unstructured":"American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 200: Early Pregnancy Loss. Obstet Gynecol. 2018;132:e197\u2013e207.","DOI":"10.1097\/AOG.0000000000002899"},{"key":"10.1016\/j.vaccine.2021.05.016_b0405","first-page":"1","article-title":"Estimated pregnancy rates and rates of pregnancy outcomes for the United States, 1990\u20132008","volume":"60","author":"Ventura","year":"2012","journal-title":"Natl Vital Stat Rep."},{"key":"10.1016\/j.vaccine.2021.05.016_b0410","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.fertnstert.2012.06.048","article-title":"Evaluation and treatment of recurrent pregnancy loss: a committee opinion","volume":"98","author":"American Society for Reproductive Medicine","year":"2012","journal-title":"Fertil Steril."},{"key":"10.1016\/j.vaccine.2021.05.016_b0415","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/ppe.12417","article-title":"Trends in Risk of Pregnancy Loss Among US Women, 1990\u20132011","volume":"32","author":"Rossen","year":"2018","journal-title":"Paediatr Perinat Epidemiol."},{"key":"10.1016\/j.vaccine.2021.05.016_b0420","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s13524-012-0113-0","article-title":"Trends in self-reported spontaneous abortions: 1970\u20132000","volume":"49","author":"Lang","year":"2012","journal-title":"Demography"},{"key":"10.1016\/j.vaccine.2021.05.016_b0425","first-page":"417","volume":"94","author":"Ammon Avalos","year":"2012","journal-title":"A systematic review to calculate background miscarriage rates using life table analysis."},{"key":"10.1016\/j.vaccine.2021.05.016_b0430","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1056\/NEJM198807283190401","article-title":"Incidence of early loss of pregnancy","volume":"319","author":"Wilcox","year":"1988","journal-title":"N Engl J Med."},{"key":"10.1016\/j.vaccine.2021.05.016_b0435","first-page":"1","article-title":"Cause-of-death Data From the Fetal Death File, 2015\u20132017","volume":"69","author":"Hoyert","year":"2020","journal-title":"Natl Vital Stat Rep."},{"key":"10.1016\/j.vaccine.2021.05.016_b0440","first-page":"1","article-title":"Fetal and Perinatal Mortality: United States, 2013","volume":"64","author":"MacDorman","year":"2015","journal-title":"Natl Vital Stat Rep."},{"key":"10.1016\/j.vaccine.2021.05.016_b0445","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1097\/AOG.0000000000004166","article-title":"Evaluating the Association of Stillbirths After Maternal Vaccination in the Vaccine Safety Datalink","volume":"136","author":"Panagiotakopoulos","year":"2020","journal-title":"Obstet Gynecol."},{"key":"10.1016\/j.vaccine.2021.05.016_b0450","unstructured":"Centers for Disease Control and Prevention. About Kawasaki Disease. Atlanta, GA: Centers for Disease Control and Prevention. https:\/\/www.cdc.gov\/kawasaki\/about.html, 2020 [Accessed 3 December 2020]."},{"key":"10.1016\/j.vaccine.2021.05.016_b0455","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1097\/INF.0000000000002239","article-title":"Spatiotemporal Analysis and Epidemiology of Kawasaki Disease in Western New York: A 16-Year Review of Cases Presenting to a Single Tertiary Care Center","volume":"38","author":"Chang","year":"2019","journal-title":"Pediatr Infect Dis J."},{"key":"10.1016\/j.vaccine.2021.05.016_b0460","first-page":"194","article-title":"Racial\/ethnic differences in the incidence of Kawasaki syndrome among children in Hawaii","volume":"69","author":"Holman","year":"2010","journal-title":"Hawaii Med J."},{"key":"10.1016\/j.vaccine.2021.05.016_b0465","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1017\/S1047951119000982","article-title":"An update on the epidemiology, length of stay, and cost of Kawasaki disease hospitalisation in the United States","volume":"29","author":"Ghimire","year":"2019","journal-title":"Cardiol Young."},{"key":"10.1016\/j.vaccine.2021.05.016_b0470","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1097\/INF.0b013e3181cf8705","article-title":"Hospitalizations for Kawasaki syndrome among children in the United States, 1997\u20132007","volume":"29","author":"Holman","year":"2010","journal-title":"Pediatr Infect Dis J."},{"key":"10.1016\/j.vaccine.2021.05.016_b0475","doi-asserted-by":"crossref","first-page":"e927","DOI":"10.1161\/CIR.0000000000000484","article-title":"Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association","volume":"135","author":"McCrindle","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.vaccine.2021.05.016_b0480","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1097\/INF.0b013e3181a66471","article-title":"Kawasaki disease after vaccination: reports to the vaccine adverse event reporting system 1990\u20132007","volume":"28","author":"Hua","year":"2009","journal-title":"Pediatr Infect Dis J."},{"key":"10.1016\/j.vaccine.2021.05.016_b0485","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.vaccine.2014.10.044","article-title":"Childhood vaccines and Kawasaki disease, Vaccine Safety Datalink, 1996\u20132006","volume":"33","author":"Abrams","year":"2015","journal-title":"Vaccine."},{"key":"10.1016\/j.vaccine.2021.05.016_b0490","first-page":"136","article-title":"Kawasaki and COVID-19 disease in children: a systematic review","volume":"2020;66Suppl 2","author":"Goncalves","year":"1992","journal-title":"Rev Assoc Med Bras"},{"key":"10.1016\/j.vaccine.2021.05.016_b0495","unstructured":"Centers for Disease Control and Prevention. Health Department-Reported cases of Multisystem Inflammatory Syndrom in Children (MIS-C) in the United States. https:\/\/www.cdc.gov\/mis-c\/cases\/index.html; 2020 [Accessed 4 December 2020]."},{"key":"10.1016\/j.vaccine.2021.05.016_b0500","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa2021756","article-title":"Multisystem Inflammatory Syndrome in Children in New York State","volume":"383","author":"Dufort","year":"2020","journal-title":"N Engl J Med."},{"key":"10.1016\/j.vaccine.2021.05.016_b0505","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.jaci.2013.10.029","article-title":"Case fatality and population mortality associated with anaphylaxis in the United States","volume":"133","author":"Ma","year":"2014","journal-title":"J Allergy Clin Immunol."},{"key":"10.1016\/j.vaccine.2021.05.016_b0510","doi-asserted-by":"crossref","unstructured":"Lee S, Hess EP, Lohse C, Gilani W, Chamberlain AM, Campbell RL. Trends, characteristics, and incidence of anaphylaxis in 2001\u20132010: Apopulation-based study. J Allergy Clin Immunol. 2017;139:182\u20138.e2.","DOI":"10.1016\/j.jaci.2016.04.029"},{"key":"10.1016\/j.vaccine.2021.05.016_b0515","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jaci.2011.04.049","article-title":"A population-based epidemiologic study of emergency department visits for anaphylaxis in Florida","volume":"128","author":"Harduar-Morano","year":"2011","journal-title":"J Allergy Clin Immunol."},{"key":"10.1016\/j.vaccine.2021.05.016_b0520","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/PEC.0b013e31828058cd","article-title":"Comparison of the incidence, etiology, and management of anaphylaxis over time","volume":"29","author":"Fuzak","year":"2013","journal-title":"Pediatr Emerg Care."},{"key":"10.1016\/j.vaccine.2021.05.016_b0525","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.jaci.2015.07.048","article-title":"Risk of anaphylaxis after vaccination in children and adults","volume":"137","author":"McNeil","year":"2016","journal-title":"J Allergy Clin Immunol."},{"key":"10.1016\/j.vaccine.2021.05.016_b0530","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/INF.0000000000001073","article-title":"Anaphylaxis After Immunization of Children and Adolescents in Germany","volume":"35","author":"Oberle","year":"2016","journal-title":"Pediatr Infect Dis J."},{"issue":"2","key":"10.1016\/j.vaccine.2021.05.016_b0535","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1080\/13696998.2019.1669329","article-title":"Primary immune thrombocytopenia in US clinical practice: incidence and healthcare burden in first 12 months following diagnosis","volume":"23","author":"Weycker","year":"2020","journal-title":"J Med Econ."},{"key":"10.1016\/j.vaccine.2021.05.016_b0540","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1080\/09537104.2019.1635687","article-title":"The incidence and clinical burden of immune thrombocytopenia in pediatric patients in the United States","volume":"31","author":"Shaw","year":"2020","journal-title":"Platelets"},{"key":"10.1016\/j.vaccine.2021.05.016_b0545","doi-asserted-by":"crossref","first-page":"e506","DOI":"10.1542\/peds.2007-1129","article-title":"A population-based, multisite cohort study of the predictors of chronic idiopathic thrombocytopenic purpura in children","volume":"121","author":"Glanz","year":"2008","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2021.05.016_b0550","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1177\/000992280404300802","article-title":"Idiopathic thrombocytopenic purpura: a 10-year natural history study at the childrens hospital of alabama","volume":"43","author":"Watts","year":"2004","journal-title":"Clin Pediatr (Phila)."},{"key":"10.1016\/j.vaccine.2021.05.016_b0555","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1542\/peds.2011-1111","article-title":"The risk of immune thrombocytopenic purpura after vaccination in children and adolescents","volume":"129","author":"O'Leary","year":"2012","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2021.05.016_b0560","doi-asserted-by":"crossref","first-page":"e687","DOI":"10.1542\/peds.2007-1578","article-title":"Risk of immune thrombocytopenic purpura after measles-mumps-rubella immunization in children","volume":"121","author":"France","year":"2008","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2021.05.016_b0565","doi-asserted-by":"crossref","first-page":"e321","DOI":"10.1542\/peds.2014-1822","article-title":"Safety of measles-containing vaccines in 1-year-old children","volume":"135","author":"Klein","year":"2015","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2021.05.016_b0570","unstructured":"Munoz FM, Cramer JP, Dekker CL, et al. Vaccine-associated enhanced disease: case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine. 2021;S0264-410X(21)00094-3. On line ahead of print."},{"key":"10.1016\/j.vaccine.2021.05.016_b0575","doi-asserted-by":"crossref","first-page":"4783","DOI":"10.1016\/j.vaccine.2020.05.064","article-title":"Consensus summary report for CEPI\/BC March 12\u201313, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines","volume":"38","author":"Lambert","year":"2020","journal-title":"Vaccine."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21005788?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21005788?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:56:39Z","timestamp":1759402599000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X21005788"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":115,"journal-issue":{"issue":"28","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S0264410X21005788"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.05.016","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"U.S. Population-Based background incidence rates of medical conditions for use in safety assessment of COVID-19 vaccines","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.05.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}